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Background: Glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase-4 (DPP4) inhibitors are a newer
class of antidiabetics named as incretin-based therapy. In addition to the homeostatic control of glucose, the
incretin-based therapy has shown beneficial effects on the cardiovascular system in preclinical and clinical studies.
However, there is limited information on their renal effects. To this end, we assessed the acute hemodynamic and
renal effects of a GLP-1 analog, Liraglutide, and a DPP4 inhibitor, MK-0626.
Methods: Experiments were performed in anesthetized male Sprague–Dawley rats. Three ascending doses of
Liraglutide (3, 9, and 27 nmol/kg/h) or MK-0626 (1 mg/kg) with or without GLP-1 peptide (2.4, 4.8, or 9.6 pmol/kg/min)
were administered. Blood pressure (BP) and heart rate (HR) were recorded from an indwelling catheter. Glomerular
filtration rate (GFR) and renal blood flow (RBF) were assessed by inulin and para-aminohippurate clearance, respectively.
Renal excretory function was assessed in metabolic studies.
Results: Both Liraglutide and MK-0626 plus GLP-1 evoked significant diuretic and natriuretic responses and increased
GFR. MK-0626 alone increased RBF. Liraglutide at 27 nmol//kg/h and MK-0626 plus GLP-1 at 9.6 pmol/kg/min also
increased HR, whereas BP was not affected.
Conclusion: The results of the present study demonstrated that a GLP-1 analog and a DPP4 inhibitor may have
beneficial effects on renal sodium and water handling. Additionally, the DPP4 inhibitor, MK-0626, favorably
affects renal hemodynamics by increasing RBF. However, exceedingly high levels of GLP-1 receptor agonists
may adversely affect the cardiovascular system in acute setting, as demonstrated by an acute increase in HR.
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Incretins, including glucagon-like peptide-1 (GLP-1) and
gastric inhibitory peptide, also known as glucose-
dependent insulinotropic polypeptide (GIP) are a class
of gastrointestinal hormones released from the small in-
testine in response to the presence of food. Incretins play
an important role in the control of blood glucose through
multiple mechanisms, predominantly via a glucose-
dependent insulinotropic effect and via suppression of* Correspondence: xiaoyan_zhou@merck.com; runforrest@comcast.net
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creativecommons.org/publicdomain/zero/1.0/glucagon release [1]. The ability to exploit the natural biol-
ogy of the incretins affords the opportunity to develop
novel therapeutic options for the treatment of type II dia-
betes. The two primary classes of incretin-based therapies
include (1) GLP-1 analogs (e.g., Exenatide and Liraglutide)
that serve to mimic endogenous GLP-1 and (2) dipeptidyl
peptidase-4 (DPP4) inhibitors (e.g. Sitagliptin, Saxagliptin,
Linagliptin, and Vildagliptin) that inhibit the enzymatic
degradation of GLP-1. In addition to their effects on the
control of glucose, incretin-based therapies have demon-
strated beneficial effects on the cardiovascular system and
metabolism in preclinical and clinical studies [2-18]. For
example, chronic administration of recombinant GLP-1
or the Exenatide analog AC3174 attenuated hypertensionicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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gliptin attenuated blood pressure (BP) elevation in young
prehypertensive spontaneously hypertensive rats (SHRs)
[4]. Sitagliptin also decreased systolic BP, increased renal
blood flow (RBF) [5], and improved endothelial function
through reducing oxidative stress in adult SHRs [6]. DPP4
inhibitor, MK-0626, prevented diastolic dysfunction and
reduced myocardial fibrosis [7] and improved neovascular-
ization in mice [8]. Exenatide improved vascular function
in rats [9]. Type II diabetic patients treated with Liraglu-
tide or Exenatide or Vildagliptin exhibited a reduction in
BP [10-12]. Saxagliptin improved microvascular function
[13] and Liraglutide induced weight loss [14] in type II
diabetes. In addition, recombinant GLP-1 infusion im-
proved cardiac function in patients with chronic heart fail-
ure or with acute myocardial infarction and severe systolic
dysfunction [15-18].
There is emerging evidence suggesting that some of
the beneficial effects of incretin-based therapy on the
cardiovascular system may be attributed to improve-
ments in renal hemodynamics and renal function
[19-25]. The underlying mechanisms responsible for
these effects remain to be fully elucidated. To this end,
we assessed the acute hemodynamic and renal effects of
a GLP-1 analog, Liraglutide, and a DPP4 inhibitor, MK-
0626. Due to the low level of endogenous GLP-1 under
conditions of fasting [26], the effects of DPP4 inhibition




Male Sprague–Dawley (SD) rats (Taconic, Petersburgh,
New York) were housed in a temperature- and humidity-
controlled facility with a 12 hour light: 12-hour dark, light
cycle. Standard rat chow (#7012, Harlan Teklad, Madison,
Wisconsin) and tap water were provided ad libitum. All
procedures utilizing experimental animals were conducted
in accordance with the Guide for the Care and Use of La-
boratory Animals, and experimental procedures were
reviewed and approved by the Institutional Animal Care
and Use Committee at Merck Research Laboratories,
Rahway, New Jersey.
Reagents
GLP-1 was purchased from CPC Scientific (San Jose,
California). MK-0626 was synthesized by Merck & Co., Inc.
Experimental procedures
After one week of acclimation, SD rats (10–12 weeks old)
were randomly divided into study groups. Rats were anes-
thetized with thiobutabarbital sodium (Inactin, 110 mg/kg,
IP; Sigma-Aldrich, St. Louis, Missouri). Core temperature
was maintained between 36 and 37°C throughout thestudy using a heating pad (Fine Science Tools Inc., Foster
City, California). Polyethylene PE-50 tubing was inserted
into the left femoral artery to permit intermittent blood
sampling, and was also connected to a pressure transducer
(NL108T2, Harvard Apparatus, Holliston, Massachusetts)
for the measurement of blood pressure (BP) and heart rate
(HR). The signal from the pressure transducer was trans-
mitted to a Ponemah data acquisition system (Data
Science International, St. Paul, Minnesota). The left
femoral vein was cannulated with PE-50 tubing for solu-
tion administration and compound delivery, respectively.
The bladder was catheterized with PE-100 tubing to allow
timed collections of urine. Upon completion of the surgi-
cal procedures, sterile isotonic saline containing 1%
albumin, 7.5% polyfructosan inulin (Fressenius Kabi
Austria GmbH, Graz, Austria), and 1.5% para-
aminohippuric acid (PAH) (Sigma-Aldrich, St. Louis,
Missouri) was infused via the left femoral vein at a
rate of 0.3 ml/100 g/h. In addition, 0.9% saline was
infused via a Y shape adapter to the left femoral vein
at a rate of 0.1 ml/100 g/h. Rats were allowed to
stabilize for ~1 hour before initiation of the study.
The experimental protocol was initiated with a
20-minute baseline urine collection, followed by ad-
ministration of either vehicle or test compound at a
rate of 0.1 ml/100 g/h for 60-minutes. At baseline
and the end of the study, blood samples (500 - 600 μl)
were collected for analysis of electrolytes (Na+, K+,
and Cl−), hematocrit, active GLP-1 levels, and DPP4
activity. Urine volumes were measured and urine was
analyzed for electrolytes (Na+, K+, and Cl−) and pH
at multiple time points during the study. GFR and
RBF were determined by inulin and PAH renal clear-
ance at baseline and the end of the study. At the
termination of each study, rats were euthanized by
CO2 inhalation.Protocol design
Protocol 1: Liraglutide studies
The aim of the study was to evaluate the acute hemo-
dynamic and renal effects of Liraglutide in anesthe-
tized rats. One group of animals received four succes-
sive infusions of saline. A second group received an
initial infusion of saline followed by three successive
infusions of Liraglutide (Lira.) at ascending doses of 3,
9 and 27 nmol/kg/h (doses were selected based on a
pilot study determining a minimal efficacious dose).
All infusions were of 20 minutes duration for each
dose. BP, HR, urinary Na+, K+, and Cl− excretion were
measured at baseline and at the end of each 20 minute
infusion period. GFR and RBF were assessed at base-
line and at the end of the last infusion period in each
animal (Figure 1).
Figure 1 Schematic of experimental protocol 1.
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The aim of the study was to evaluate the acute
hemodynamic and renal effects of MK-0626 in the
presence or absence of an infusion of exogenous GLP-
1 in anesthetized rats. Animals were randomized into
8 experimental groups (n = 6 - 8) (Table 1): Group 1.
Saline plus saline; Group 2. Saline plus GLP-1 2.4
pmol/kg/min; Group 3. Saline plus GLP-1 4.8 pmol/
kg/min; Group 4. Saline plus GLP-1 9.6 pmol/kg/min;
Group 5. MK-0626 1 mg/kg plus saline; Group 6. MK-
0626 plus GLP-1 2.4 pmol/kg/min; Group 7. MK-0626
plus GLP-1 4.8 pmol/kg/min; and Group 8. MK-0626
plus GLP-1 9.6 pmol/kg/min. Saline or MK-0626
(1 mg/kg) was given by intravenous bolus injection
immediately prior to saline or GLP-1 intravenous infu-
sion. Parameters measured are the same as described
in Protocol 1 (Figure 2).
Doses selected for liraglutide and GLP-1 were based
on the results from our pilot studies showing natri-
uresis/diuresis with plasma levels greater than the EC50
for activation of the GLP-1 receptor.Table 1 Study groups in Figure 2
Groups Treatment
1 Saline (iv bolus) followed by saline
2 Saline (iv bolus) followed by GLP-1 @ 2.4 pmol/kg/min
3 Saline (iv bolus) followed by GLP-1 @ 4.8 pmol/kg/min
4 Saline (iv bolus) followed by GLP-1 @ 9.6 pmol/kg/min
5 MK-0626 (1 mg/kg) (iv bolus) followed by saline iv infusion
6 MK-0626 (1 mg/kg) (iv bolus) followed by GLP-1 @ 2.4
pmol/kg/min
7 MK-0626 (1 mg/kg) (iv bolus) followed by GLP-1 @ 4.8
pmol/kg/min
8 MK-0626 (1 mg/kg) (iv bolus) followed by GLP-1 @ 9.6
pmol/kg/min
iv. intravenous.Analytical techniques
Na+, K+, and Cl− concentrations in plasma and urine were
measured by a Roche Modular Chemistry System (Roche
Diagnostics, Indianapolis, Indiana). Hematocrit was deter-
mined using a HESKA I-STAT Hematology Analyzer
(HESKA, Fribourg, Switzerland). Urine pH was measured
by a pH meter (Fisher Scientific, Pittsburgh, Pennsylvania).
Inulin and PAH concentrations in plasma and urine were
determined by colorimetric assays. The plasma concentra-
tion of active GLP-1 was determined using an Enzyme-
Linked Immunosorbent Assay method (BioNebraska,
Omaha, Nebraska). Plasma DPP4 activity was measured
using a continuous fluorometric assay with the substrate
Gly-Pro-AMC, which is cleaved by DPP4 to release the
fluorescent AMC leaving group.
Statistical analysis
All data are presented as mean ± standard error of the
mean (SE). A paired Student’s t-test was used for compari-
sons of all treatment time points with baseline. A p value
of < 0.05 is considered to be statistically significant.
Results
Hemodynamic and renal effects of Liraglutide
Initial studies evaluated the acute hemodynamic and renal
effects of Liraglutide. The intravenous infusion of Liraglu-
tide (9 and 27 nmol/kg/h) significantly increased HR; BP
remained unchanged at all doses of Liraglutide (Table 2).
Liraglutide (9 and 27 nmol/kg/h) also evoked significant
diuresis (6.7 and 7.0 fold), natriuresis (38.3 and 56.4 fold),
chloruresis (20.3 and 22.9 fold), and kaliuresis (4.7 and 3.4
fold) (compared to pre-Liraglutide administration, all
p < 0.01, Figure 3). Urine pH was also significantly in-
creased from a baseline of 6.4 ± 0.1 to 7.1 ± 0.1 and 7.5 ±
0.1 at doses of 9 and 27 nmol/kg/h, respectively (p < 0.05).
GFR and RBF were measured at baseline and at the con-
clusion of the last infusion of either saline or Liraglutide
Figure 2 Schematic of experimental protocol 2.
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baseline to 1.4 ± 0.05 ml/min/kw(g) post-Liraglutide infu-
sion (p < 0.05). RBF was not significantly different between
baseline and post-Liraglutide infusion (Table 3). At the end
of the study, the plasma K+ concentration was significantly
decreased (3.3 ± 0.08 vs. 4.1 ± 0.15 mmol/l at baseline,
p<0.05) and the hematocrit was significantly increased
(43.9 ± 0.7 vs. 39.9 ± 0.4 at baseline, p<0.05) only in animals
that received Liraglutide. Presumably these changes were
a consequence of Liraglutide induced kaliuresis and
volume contraction. At the end of the Liraglutide infusion,
the plasma glucose level was slightly higher than at
baseline (Table 3); we speculate this is attributable to
the substantial diuresis/natriuresis induced by Liraglutide,
which led to extracellular volume contraction and
hemoconcentration.Hemodynamic and renal effects of MK-0626 and GLP-1
The effects of the DPP4 inhibitor, MK-0626, alone and
in the presence of GLP-1, on hemodynamic and renal
effects were evaluated. Baseline plasma GLP-1 levels are
exceedingly low in fasted animals and hence are onlyTable 2 Effects of Liraglutide (all three doses) on blood
pressure and heart rate
BP (mmHg) HR (bpm)
Baseline→treatment Baseline→treatment
Saline alone 121.8 ± 5.0→116.0 ± 4.7 378.6 ± 9.5 →360.1 ± 6.3
Lira 3 nmol/kg/h 125.5 ± 1.5→124.9 ± 1.8 393.3 ± 7.8→397.9 ± 12.2
Lira 9 nmol/kg/h 125.5 ± 1.5→ 127.3 ± 2.4 393.3 ± 7.8→415.0 ± 12.6*
Lira 27 nmol/kg/h 125.5 ± 1.5→ 129.4 ± 1.8 393.3 ± 7.8→425.9 ± 14.3*
Lira, Liraglutide. *P < 0.05 post- vs. pre-treatment (baseline). In the saline alone
group, BP and HR were not changed through the study; data shown in the
table are the 1st and last study period. Baseline refers to the 20 minutes period
prior to administration of saline or Liraglutide.marginally increased in the presence of DPP4 inhibition.
Accordingly, exogenous GLP-1 was infused to achieve
plasma GLP-1 levels similar to those observed following
a meal. Plasma DPP4 activity was inhibited by greater
than 90% in animals that received MK-0626 (1 mg/kg).
The infusion of exogenous GLP-1 at doses of 2.4, 4.8
and 9.6 pmol/kg/min induced a step-wise increase in
plasma active GLP-1 levels, which were further en-
hanced in animals previously administered MK-0626
(Figure 4). In animals that received MK-0626 plus the
high dose of GLP-1 (9.6 pmol/kg/min), a significant in-
crease in HR was observed (Table 4). BP and HR were
not significantly affected by any of the other treatment
paradigms of MK-0626, GLP-1 or combinations thereof.
MK-0626 alone had no significant effect on either diur-
esis or natriuresis (Figure 5). GLP-1 alone induced a
modest, albeit significant increase in diuresis, natriuresis,
chloruresis and kaliuresis. However, MK-0626 plus in-
creasing doses of GLP-1 administration evoked a dose
dependent increase in diuresis, natriuresis, chloruresis
and kaliuresis (Figure 5). Urine pH was also significantly
increased by combinations of MK-0626 plus exogenous
GLP-1 (Table 5). The effects of MK-0626 and GLP-1 on
GFR and RBF are complex. GFR was increased in all ani-
mals that received MK-0626 but these effects were not
further enhanced in the presence of increasing doses of
GLP-1 (Figure 6b). In animals that received GLP-1
alone, there was a modest increase in GFR but the ef-
fects did not exhibit any dose-dependence (Figure 6a). A
similar pattern of changes and absence of dose-
dependence was observed for the effects of MK-0626
plus GLP-1 on RBF (Figure 6c,d). However, the magni-
tude of change was more variable with MK-0626 plus
GLP-1. Furthermore, a significant effect of GLP-1 alone
on RBF was only observed at the highest dose of GLP-1
(9.6 pmol/kg/min). The plasma K+ concentration was
lower and the hematocrit was not significantly changed
** P < 0.01 vs. baseline. 
Figure 3 Effects of Liraglutide on urine flow rate, urinary Na+, K+, and Cl− excretion. Liraglutide was administered by three successive
infusions of ascending doses of (3, 9 and 27 nmol/kg/h), 20 minutes for each dose. Data are mean ± SEM (n = 6 for saline group, n = 8 for Liraglutide
group). ** P < 0.01 vs. baseline. Baseline refers to the 20 minutes period prior to administration of saline or Liraglutide.
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tion (Table 6). Importantly, no significant changes in
plasma insulin or glucose levels were observed at the
end of study in animals that received MK-0626 plus
GLP-1 administration (Table 7).
Discussion
Modulation of the incretin axis as a therapeutic option for
the treatment of type II diabetes has achieved considerable
success. Emerging evidence indicates that these ap-
proaches not only have beneficial effects on metabolic pa-
rameters but also have favorable effects on cardiovascular
function [2-18]. The studies described herein have focusedTable 3 Effects of Liraglutide (at the end of the study) on
renal function, blood glucose and insulin
Saline Liraglutide
Baseline Treatment Baseline Treatment
GFR (ml/min/kw(g)) 1.3 ± 0.16 1.5 ± 0.21 0.9 ± 0.09 1.4 ± 0.05*
RBF (ml/min/kw(g)) 8.3 ± 0.49 10.5 ± 1.18 6.8 ± 0.99 8.4 ± 1.38
Glucose (mg/dl) 132.3 ± 3.33 140.4 ± 5.6 144.9 ± 4.2 168.9 ± 10.7*
Insulin (ng/ml) 2.2 ± 0.25 3.1 ± 0.62 3.0 ± 0.5 3.6 ± 0.7
*P < 0.05 post- vs. pre-treatment (baseline). Baseline refers to the 20 minutes
period prior to administration of saline or Liraglutide.on the acute effects of GLP-1 on hemodynamics and renal
function in anesthetized normotensive and normogly-
cemic rats. The studies compared a metabolically stable
GLP-1 analog, Liraglutide, with a DPP4 inhibitor, MK-
0626.
One of the principal findings of these studies was that
elevated circulating levels of active GLP-1 or the GLP-1
analog, Liraglutide, evoked a concentration dependent in-
crease in both diuresis and natriuresis. Circulating levels** P < 0.01 vs. baseline. 
Figure 4 Effects of exogenous GLP-1 infusion on plasma active
GLP-1 level. Data are mean ± SEM. ** P < 0.01 vs. baseline. Baseline
refers to the 20 minutes period prior to IV administration of saline
or MK-0626.
Table 4 Effects of MK-0626 plus GLP-1 on blood pressure and heart rate
BP (mmHg) HR (bpm)
Baseline→treatment Baseline→treatment
MK-0626 + saline 123.5 ± 3.7 →121.9 ± 3.9 381.2 ± 10.0→ 380.9 ± 10.3
MK-0626 + GLP-1 2.4 pmol/kg/min 121.1 ± 4.8 →118.7 ± 3.7 365.1 ± 12.6→385.1 ± 8.6
MK-0626 + GLP-1 4.8 pmol/kg/min 125.7 ± 3.7 →123.5 ± 1.6 401.0 ± 6.5 →406.7 ± 9.2
MK-0626 + GLP-1 9.6 pmol/kg/min 124.7 ± 3.0→122.0 ± 2.3 386.9 ± 8.7→406.1 ± 8.5*
*P < 0.05 vs. baseline. Baseline refers to the 20 minutes period prior to IV administration of saline or MK-0626.
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pmol/L; but increase rapidly upon food intake to approxi-
mately 50 pmol/L [26]. GLP-1 is rapidly inactivated within
the circulation predominately by DPP4 and has a circulat-
ing half-life of only 1 to 2 minutes. DPP4 inhibitors raise
circulating plasma levels of GLP-1 by preventing its pro-
teolytic degradation [27-29]. In the studies reported
herein, baseline plasma GLP-1 concentrations are very
low (<10 pmol/L; Figure 4), consequently administration
of the DPP4 inhibitor MK-0626 alone only marginally in-
creased circulating GLP-1 levels to 5.5 pmol/L from 3.4
pmpol/L. Therefore, in order to increase circulating GLP-
1 to levels observed in the post-prandial state, animals
were infused with exogenous GLP-1 either alone or fol-
lowing administration of MK-0626. Under these condi-
tions, plasma active GLP-1 levels increased in proportion
to the GLP-1 infusion rate. Furthermore, in the presence* P < 0.05, ** P < 0.01
Figure 5 Effects of MK-0626/GLP-1 on urine flow rate, urinary Na+, Cl
baseline. Baseline refers to the 20 minutes period prior to IV administrationof MK-0626 at a dose that inhibits DPP4 activity by >90%,
plasma active GLP-1 levels were similar to or greater than
those measured in the postprandial state (approximately
40 - 60 pmol/l in rats). Importantly, the increased plasma
levels of GLP-1 exceeded the concentration of GLP-1 (10
pmol/L) required for half maximal activation of the rat
GLP-1 receptor (EC50) in vitro (unpublished internal
data). Our observation, that both diuresis and natriuresis
positively correlated with plasma GLP-1 levels (Figures 4
and 5), is consistent with the renal effects being mediated
by GLP-1 activation of the GLP-1 receptor. This conten-
tion is further supported by results of the studies with Lir-
aglutide. In these studies increased diuresis and natriuresis
were observed at Liraglutide doses of 9 and 27 pmol/Kg/h
which achieved Liraglutide concentrations 18 and 50-fold
above the EC50 value for activation of the GLP-1 receptor
by Liraglutide. vs. baseline. 
− and K+ excretion. Data are mean ± SEM. *P < 0.05, **P < 0.01 vs.
of saline or MK-0626.
Table 5 Effects of MK-0626 plus GLP-1 on urine pH
Baseline Treatment
MK-0626 + saline 6.07 ± 0.17 6.25 ± 0.20
MK-0626 + GLP-1 2.4 pmol/kg/min 6.09 ± 0.14 6.93 ± 0.14*
MK-0626 + GLP-1 4.8 pmol/kg/min 6.03 ± 0.11 6.92 ± 0.12**
MK-0626 + GLP-1 9.6 pmol/kg/min 6.19 ± 0.11 6.90 ± 0.07**
*P < 0.05, **p < 0.01 vs. baseline. Baseline refers to the 20 minutes period prior
to IV administration of saline or MK-0626.
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Liraglutide and MK-0626 plus GLP-1 is not fully under-
stood but is likely attributable to effects on the renal tu-
bules. The contribution to natriuresis and diuresis by an
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Figure 6 Effect of MK-0626 and/or GLP-1 on GFR and RBF. GFR, glome
on GFR and RBF, respectively. b and d, effects of MK-0626+GLP-1 on GFR and
period prior to IV administration of saline or MK-0626.by either Liraglutide or MK-0626 plus GLP-1 is modest
and is also not dose-dependent. We speculate that the renal
tubular effects of Liraglutide or MK-0626 plus GLP-1 may
be mediated, at least in part, by GLP-1 receptor activation
and consequent inhibition of sodium hydrogen exchanger 3
(NHE3). There are several lines of evidence supporting our
contention: 1. GLP-1 receptor mRNA and protein are
expressed in the proximal tubular cells in rats and pigs
[20,30,31]; while a recent study reported that the GLP-1
receptor is exclusively localized in the smooth muscle cells
of arterioles and blood vessels lining the kidney in the pri-
mates and humans [32]. The discordant results for GLP-1
receptor localization could be due to differences in detec-
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rular filtration rate. RBF, renal blood flow. a and c, effects of saline+GLP-1
RBF, respectively. *p < 0.05 vs. baseline. Baseline refers to the 20 minutes
Table 6 Effects of MK-0626 plus GLP-1 on plasma K+ and hematocrit
Group K+(mmol/l) Hematocrit (%)
Baseline→treatment Baseline→treatment
MK-0626 + Saline 4.4 ± 0.14→4.2 ± 0.10 40.0 ± 0.8→38.2 ± 0.6
MK-0626 + GLP-1 2.4 pmol/kg/min 4.5 ± 0.08→3.8 ± 0.09** 40.1 ± 0.7→39.7 ± 0.5
MK-0626 + GLP-1 4.8 pmol/kg/min 4.4 ± 0.09→3.6 ± 0.05** 39.6 ± 0.6→39.8 ± 0.5
MK-0626 + GLP-1 9.6 pmol/kg/min 4.4 ± 0.10→3.6 ± 0.08** 40.5 ± 0.5→41.1 ± 0.6
**p < 0.01 vs. baseline. Baseline refers to the 20 minutes period prior to IV administration of saline or MK-0626.
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hibits sodium re-absorption in renal proximal tubule
cells [31,32]. 3. Renal microperfusion studies showed
that GLP-1 significantly decreases NHE3-mediated bicar-
bonate reabsorption in the intact renal proximal tubule
[20]. 4. Intravenous infusion of GLP-1 in anesthetized rats
increased urine flow and urinary excretion of sodium,
potassium, bicarbonate [19,20] and also increased frac-
tional excretion of lithium [19], an index of proximal
tubular reabsorption [33]. Finally, our observation of an
increase in urine pH in animals that received Liraglutide
or MK-0626 plus GLP-1 is consistent with blockade of a
sodium-hydrogen exchange mechanism.
In addition to renal tubular effects, Liraglutide, GLP-1,
or MK-0626 plus GLP-1 promoted an increase in GFR.
The mechanism or mechanisms for the increase in GFR
are not clear. One potential contribution is through dilata-
tion of renal afferent arterioles. The GLP-1 receptor is
widely expressed in the vasculature [34,35]; GLP-1 causes
vasorelaxation in the isolated rat aorta and femoral artery
[36,37] and increases blood flow in the forearm or the bra-
chial artery in humans [38,39]. Importantly, the GLP-1 re-
ceptor is expressed in the renal artery [5,40], and as shown
by others and in the studies described here, GLP-1 and
GLP-1 receptor agonists increase RBF in anesthetized rat
studies [19,20]. The absence of a dose-dependent effect of
either GLP-1 or Liraglutide on either GFR or RBF indi-
cates that increased RBF is not the sole determinant of the
increase in GFR. Glomerular filtration is regulated and
maintained by numerous physiological processes. In par-
ticular, changes in tubuloglomerular feedback (TGF) could
counteract other influences on GFR [41,42]. The increased
delivery of sodium chloride to the macula densa as a result
of inhibiting NHE3 in the proximal tubule by GLP-1Table 7 Effects of MK-0626 plus GLP-1 on glucose and insulin
Glucose
Baseline
MK-0626 + Saline 134.9 ± 6
MK-0626 + GLP-1 2.4 pmol/kg/min 120.6 ± 7
MK-0626 + GLP-1 4.8 pmol/kg/min 136.5 ± 7
MK-0626 + GLP-1 9.6 pmol/kg/min 122.6 ± 4
Baseline refers to the 20 minutes period prior to IV administration of saline or MK-0receptor activation should trigger enhancement of TGF
and hence a reduction of GFR. Indeed, a proximal tubule
diuretic such as benzolamide activates TGF and lowers
GFR [43]. Moreover, natriuresis and diuresis may result in
volume contraction and activation of the sympathetic ner-
vous system and renin-angiotensin aldosterone system
[44-46], both of which could lower GFR. Clearly, a more
detailed assessment of the effects of GLP-1 receptor acti-
vation with respect to effects on renal vascular tone, TGF,
neurohormonal activation and the interplay for these re-
sponses is warranted to fully understand the observed
changes in GFR and RBF.
It is interesting to note that MK-0626 alone increased
RBF even in the absence of GLP-1 administration. This
raises the possibility of a GLP-1 receptor independent
mechanism contributing to the RBF effect of MK-0626.
Although GLP-1 is the primary DPP-4 substrate, DPP-4
also cleaves multiple peptides including GIP, stromal cell
derived factor type 1 α (SDF1α), neuropeptide Y (NPY),
peptide YY (PYY), B-type (brain) natriuretic peptide
(BNP), glucagon like peptide-2, and other substrates [47].
Direct effects of these peptides on renal hemodynamics
were not tested in the present study. Future studies are
warranted.
Liraglutide at the highest dose administered (27 nmol/
kg/h) and the combination of MK-0626 with a high dose
of GLP-1 (9.6 pmol/kg/min) evoked significant increases
in heart rate while not affecting blood pressure. These
observations are consistent with persistent small in-
creases in HR reported in clinical studies with Liraglu-
tide [48]. Similarly, MK-0626 plus the utilized highest
GLP-1 dose also increased HR. Our internal experiments
demonstrated the EC50 of Liraglutide on rat GLP-1 re-
ceptor is 2.2 nmol/l (unpublished data). As mentioned(mg/dl) Insulin (ng/ml)
→treatment Baseline→treatment
.0→135.8 ± 7.3 2.5 ± 0.2→2.7 ± 0.1
.6→142.7 ± 14.7 2.7 ± 0.5→2.2 ± 0.2
.9→136.1 ± 8.8 1.8 ± 0.2→1.5 ± 0.2
.1→131.1 ± 4.5 2.2 ± 0.2→2.6 ± 0.4
626.
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achieved a plasma concentration of 110.5 ± 18.8 nmol/l
(50-fold greater than the EC50 for activation of the
GLP-1 receptor by Liraglutide). Similarly administration
of MK-0626 plus GLP-1(9.6 pmol/kg/min) achieved a
plasma concentration of active GLP-1 of 121.8 ± 11.5
pmol/L (12-fold greater than the EC50 for activation of
the GLP-1 receptor by GLP-1). Whether these levels of
Liraglutide or GLP-1 are sufficient to directly activate
GLP-1 receptors in the heart or potentially in the CNS
are unclear. Alternatively, these high levels of Liraglutide
or GLP-1 may be activating other GLP-1 related recep-
tors to evoke an increase in heart rate.
To summarize, we have shown that the GLP-1 analog,
Liraglutide, and a DPP4 inhibitor, MK-0626, produced
favorable effects on sodium and water handling, which is
likely achieved via GLP-1 receptor activation in the renal
proximal tubules. Exceedingly high levels of GLP-1 re-
ceptor agonists which activate GLP-1 receptors may
contribute to the acute HR increase. Additionally, we
also have shown that MK-0626 acutely increased RBF,
which appears to be mediated, at least in part, by a GLP-
1 receptor independent mechanism. Our findings sug-
gest that a GLP-1 analog or a DPP4 inhibitor may pro-
vide additional renal effects beyond glycemic control.
Although convincing, there are a few limitations. First,
the present studies were performed in acute settings
(mostly 20-minute for each observation period). Second,
normotensive and normoglycemic rats were utilized in
the present studies. Third, study animals were anesthe-
tized in order to monitor renal function by collecting
urine from bladder precisely through the study. There-
fore, the findings from the present studies may not ne-
cessarily apply to chronic setting or in diseased animal
models. Further chronic studies particularly in diabetic
models or in models of renal dysfunction are warranted.
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